44 results about "Angiotensin Receptor Blockers" patented technology

Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to the invention include a VDRA/Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.

Disclosed are methods of treating neuropsychiatric diseases, neuromuscular diseases, viral infections, neurodegenerative diseases and ricin poisoning using angiotensin II receptor blockers.

Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

Numerous common diseases are associated with the ACE D/D genotype and will respond to an adequate tissue-inhibitory dose of ACE inhibitors such as quinapril. Detailed genotype studies establish the association and several of these diseases are successfully treated using higher than normal dosages of ACE inhibitors, especially hydrophobic ACE inhibitors. ACE inhibitors have also been found to be useful in inhibiting apoptosis and aging in general. Formulations containing a second active agent such as a diuretic, or a compound such as furosemide 20 mg/day (for creatinine<2.5 mg/dl) or furosemide 40 mg/day (for creatinine>2.5 mg/dl), are used to prevent fluid retention and congestive heart failure in patients with renal failure. The ACE inhibitors can also be combined with an angiotensin receptor blocker.

Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (PTSD). In particular, described herein are angiotensin receptor blockers (ARBs), and in particular the combination of one or more ARB (such as telmisartan) and an agent that enhances the delivery of the ARB across the blood-brain barrier (such as minocycline). PTSD may be treated using a combination of telmisartan and minocycline at levels of each that are, by themselves, infective to treat PTSD. Also described herein are methods for treating PTSD by first identifying patents for whom the use of an ARB treatment would be effective, by determining that patient has a dysfunction in their angiotensin converting enzyme and/or other genes in the autonomic arousal axis.

Over 40 common diseases, in addition to congestive heart failure (CHF) due to hypertension (HTN) or non-insulin dependent diabetes mellitus (type II diabetes mellitus) (NIDDM), atherosclerotic peripheral vascular disease (ASPVD) due to HTN or NIDDM, and chronic obstructive pulmonary disease; emphysema (COPD), are associated with the ACE D/D genotype and should also respond to an adequate tissue-inhibitory dose of ACE inhibitors such as quinapril. Several of these diseases have now been successfully treated using higher than normal dosages of ACE inhibitors, especially hydrophobic ACE inhibitors, with good outcomes. ACE inhibitors have also been found to be useful in inhibiting apoptosis and aging in general. Dosages that have been utilized are typically greater than quinapril at a dose of 40 to 80 mg/day, i.e. up to 1 mg/kg per day for a “typical” 80 kg patient. New formulations of ACE inhibitors have been developed for these higher dosages, including 80 mg tablets, controlled and/or sustained release formulations, and formulations containing a second active agent such as a diuretic, or a compound such as furosemide 20 mg/day (for creatinine <2.5 mg/dl) or furosemide 40 mg/day (for creatinine >2.5 mg/dl), to prevent fluid retention and congestive heart failure in patients with renal failure. The ACE inhibitors can also be combined with an angiotensin receptor blocker.

Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.

The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-10. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophilin inhibitors.

Provided herein are pharmaceutical compositions for the treatment of wounds, including chronic wounds and diabetic ulcers. The pharmaceutical compositions, which comprise valsartan, inhibit angiotensin receptors in the wound bed. Also provided herein are methods of making the pharmaceutical compositions of the invention, and methods for treating wounds in patients in need thereof.

This invention discloses valine butanoyl biphenyl compound, which is prepared by connecting biphenyl, valine and furodiazole, and is a receptor blocker of angiotensin II. The compound can be used to manufacture drugs for preventing or treating hypertension, coronary artery disease, cardiovascular, cerebrovascular and nephric vascular diseases, migraine, and pulmonary artery hypertension.

The invention discloses an amino acid phenyl benzene, which is comprised of phenyl benzene, amino acid and oxdiazole organically. It is the receptor blocking agent for angiotensin II and can be used for preparing medicine for treating or preventing high blood pressure, coronary disease, cerebrovascular disease, cephalagra, pulmonary arterial hypertension and so on.

Methods are provided to prevent and to treat fibromyalgia by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, calcium channel blocker, phosphodiesterase inhibitor, alpha blocker, or beta blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated. The compositions promote neo capillary formation, whereby symptoms of fibromyalgia are treated, reduced, or ameliorated.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Methods are provided to prevent and to treat urogenital (e.g., urovaginal) atrophy syndrome of menopause by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, or calcium channel blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated.

The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, a calcium channel blocker, and a beta-blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.

This invention relates to a kind of amino acid diphenyl compound and its medicine application. This compound is organically joined up by diphenyl and amino acid oxadiazole, is receptor blocking agent of angiotensin ii, could be used in preparing drug that prevent or treatment hypertension, coronary heart disease, heart- brain- renal vascular disease, migraine, pulmonary hypertension and so on.

A method is provided to prevent and to treat Osteoarthritis syndrome by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat Osteoarthritis syndrome by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by intra-articular injection into the affected joint or administered by topical application to the skin in a region of the affected joint, so as to increase the capillary network and articular blood supply to the joint or to increase hyaluronic acid production to the articular cartilage, bones, articular ligaments, synovia tissue and other soft tissues.

The present invention provides a fimasartan compound. The Fimasartan (1) has a chemical name of 2-butyl-5-dimethylaminothiocarbamoylmethyl-6-methyl-3-[[2'-(1H) tetrazole-5-yl)biphenyl-4-yl-]methyl]pyrimidine-4(3H)-one, and is a novel angiotensin II receptor blocker antihypertensive drug. Preclinical studies and clinical trials show that the Fimasartan is safer than other ARB (angiotensin receptorblocker) drugs, and more effective in reducing diastolic blood pressure of hearts, and has good tolerance. The Fimasartan compound has characteristic peaks at 18.74, 21.10, and 24.00 in an X-ray powder diffraction spectrum.